PFIZER News & Analysis

All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far. 

We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.

We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.

Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

We think these holdings are bargains.

Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.

Energy stocks are on a tear and there's more to come, says Morningstar.

We believe Pfizer and BioNTech's vaccine is set up for emergency use this year, followed by full approval in 2021 pending supportive final data.

These undervalued wide-moat stocks earn low uncertainty ratings, writes Susan Dziubinski.

We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.